Dual Regulatory Roles of CPT1C in Chronic Stress-Induced Depression-Related Outcomes

Why It Matters

Targeting CPT1C could enable novel, metabolism‑based antidepressant strategies that restore AMPA‑mediated transmission without the side effects of conventional drugs.

Key Takeaways

• CPT1C boosts GluA1 surface trafficking via SAC1 lipid signaling
• CPT1C suppresses mTORC1 through AMPK activation
• CPT1C loss rescues stress‑induced synaptic loss
• Dual role links metabolism to depression circuitry
• Potential therapeutic target for rapid‑acting antidepressants

Pulse Analysis

Chronic stress reshapes excitatory synapses, a core feature of major depressive disorder. Recent work highlights CPT1C, a brain‑specific isoform of the fatty‑acid‑transferase family, as a critical metabolic sensor that modulates AMPA‑receptor dynamics. By interacting with the phosphoinositide phosphatase SAC1, CPT1C promotes the palmitoylation‑dependent insertion of GluA1‑containing receptors into the postsynaptic membrane, thereby enhancing synaptic strength in the hippocampus and nucleus accumbens. This mechanism aligns with the glutamate hypothesis of depression, which attributes mood dysregulation to impaired glutamatergic transmission.

Conversely, CPT1C also engages the AMPK‑TSC2‑mTORC1 axis, curbing protein synthesis pathways that are hyperactive after prolonged stress. In mouse models, CPT1C knockout or selective inhibition restores mTORC1 balance, prevents dendritic spine loss, and normalizes behavioral readouts such as the tail‑suspension and social defeat tests. These dual actions reconcile seemingly contradictory findings on AMPA‑receptor trafficking and mTOR signaling, suggesting that CPT1C functions as a molecular switch that integrates nutrient status with synaptic plasticity.

The therapeutic implications are significant. Existing rapid‑acting antidepressants like ketamine act downstream of AMPA‑receptor activation; modulating CPT1C could achieve comparable synaptic reinforcement while avoiding dissociative side effects. Moreover, CPT1C’s metabolic footprint offers a biomarker‑friendly avenue for patient stratification, especially in individuals with comorbid metabolic syndrome. As drug discovery pivots toward precision neuro‑metabolism, CPT1C stands out as a promising target to recalibrate excitatory circuits and deliver faster, more durable relief for depression sufferers.